MDT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Medtronic is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 who wants to act now. The business is stable and restructuring could help over time, but the current technical trend is still weak, analyst targets are being cut, and there is no strong proprietary buy signal. I would hold off on adding aggressively at this moment and wait for clearer trend improvement.
MDT is trading pre-market at 77.08, just above the pivot level of 77.601? Actually it remains near the pivot zone and below the first resistance at 80.187. The trend remains bearish: SMA_200 > SMA_20 > SMA_5, which signals a downtrend. MACD histogram is -0.102 and still below zero, though the negative momentum is slightly contracting. RSI_6 is 42.723, neutral but weak, showing no strong rebound signal yet. Overall, the chart suggests a cautious, range-to-bearish setup rather than a clean entry.
Restructuring is a meaningful long-term catalyst, including the diabetes separation and focus on core businesses. News flow highlights profitability improvements, new product launches, and the Hugo surgical robot as a potential growth driver. Hedge funds are buying, with buying activity up 167.88% over the last quarter, which is a supportive institutional signal. The company also has a strong dividend history, which is attractive for long-term holders.
Analyst sentiment has softened materially, with multiple firms cutting price targets in April and May. Jefferies, UBS, Truist, Stifel, Piper Sandler, and others lowered targets, and several maintain Hold or Neutral ratings. Citi also removed MDT as a top pick. News notes the stock is down about 40% from its 2021 peak, reflecting weak market confidence. There is no AI Stock Picker signal and no recent SwingMax buy signal today.
Latest quarter financial data was not provided, so there is no direct quarter-by-quarter revenue or EPS trend to evaluate. The available commentary indicates Medtronic's updated guidance was affected by the MiniMed IPO timing, one-time expenses, and a $157M Q4 charge tied to future payments related to MiniMed Flex. That points to near-term earnings pressure, but the company is still being repositioned toward higher-margin core segments.
Recent analyst trend is negative to mixed: several firms lowered price targets, including Jefferies to $95, UBS to $90, Truist to $95, Stifel to $95, Piper Sandler to $91, and Evercore also trimmed its target. Ratings are mostly Hold/Neutral with a few Buy/Outperform names still remaining, such as Mizuho, Evercore, Citi, and Argus. The Wall Street pros case is that restructuring, focused core businesses, and long-term market opportunity could improve growth. The cons case is that growth remains too slow, guidance has been pressured by the diabetes separation, and the stock is losing target support.
